SS
CYTK icon

Steve Schonfeld’s Cytokinetics CYTK Stock Holding History

Steve Schonfeld’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,200
Closed -$65K – 2109
2024
Q2 		$65K Sell
1,200
-6,300
-84% -$380K ﹤0.01% 1911
2024
Q1 		$526K Buy
7,500
+3,700
+97% +$286K ﹤0.01% 1466
2023
Q4 		$317K Buy
+3,800
New +$138K ﹤0.01% 1415

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steve Schonfeld's CYTK Position: Q2 2026 in Review

Steve Schonfeld reduced its Cytokinetics (CYTK) stake by 47% in Q2 2026, selling an estimated $3.46M and leaving 53,354 shares worth $4.55M. The position accounts for 0.02% of the portfolio, ranked #680.

Steve Schonfeld first reported a position in CYTK in Q3 2016 and has held it in 17 quarters since. The position peaked at $7.05M in Q1 2025. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Steve Schonfeld held 53,354 shares of Cytokinetics worth $4.55M as of Q2 2026.
  • Steve Schonfeld sold 48,211 Cytokinetics shares in Q2 2026, an estimated $3.46M.
  • Cytokinetics made up 0.02% of Steve Schonfeld's portfolio in Q2 2026, its #680 holding.
  • Steve Schonfeld first reported a position in Cytokinetics in Q3 2016 and has held it in 17 quarters since.
  • Steve Schonfeld's Cytokinetics position peaked at $7.05M in Q1 2025.
  • 479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.